Ad
related to: 1 ethyl 3 hydrochloride tablets
Search results
Results from the WOW.Com Content Network
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, EDAC or EDCI) is a water-soluble carbodiimide usually handled as the hydrochloride. [1] It is typically employed in the 4.0-6.0 pH range. It is generally used as a carboxyl activating agent for the coupling of primary amines to yield amide bonds.
Ethacizine (ethacyzine) is a class Ic antiarrhythmic agent, related to moracizine. [2] It is used in Russia and some other CIS countries for the treatment of severe and/or refractory ventricular and supraventricular arrhythmias, especially those accompanied by organic heart disease.
PRL-8-53 is a nootropic substituted phenethylamine that has been shown to act as a hypermnesic drug in humans; it was first synthesized by medical chemistry professor Nikolaus Hansl at Creighton University in the 1970s as part of his work on amino ethyl meta benzoic acid esters.
A common way to synthesize an NHS-activated acid is to mix NHS with the desired carboxylic acid and a small amount of an organic base in an anhydrous solvent. A coupling reagent such as dicyclohexylcarbodiimide (DCC) or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is then added to form a highly reactive activated acid intermediate.
Rilmazafone [1] (リスミー, Rhythmy, previously known as 450191-S) is a water-soluble prodrug developed in Japan. [2] Inside the human body, rilmazafone is converted into several benzodiazepine metabolites that have sedative and hypnotic effects. [3] [4] [5]
Tapentadol, sold under the brand names Nucynta and Palexia among others, is a synthetic opioid analgesic of the benzenoid class with a dual mode of action as a highly selective full agonist of the μ-opioid receptor and as a norepinephrine reuptake inhibitor (NRI). [7]
Triethylenetetramine (TETA and trien), also known as trientine when used medically, is an organic compound with the formula [CH 2 NHCH 2 CH 2 NH 2] 2.The pure free base is a colorless oily liquid, but, like many amines, older samples assume a yellowish color due to impurities resulting from air oxidation.
In June 2024, the US Food and Drug Administration (FDA) approved Phenylpropanolamine hydrochloride chewable tablets for the control of urinary incontinence due to a weakening of the muscles that control urination (urethral sphincter hypotonus) in dogs. [78] [79] [80] This is the first generic phenylpropanolamine hydrochloride chewable tablets ...
Ad
related to: 1 ethyl 3 hydrochloride tablets